Recurrence rates in ocular non-infectious uveitis according to US FDA criteria or Rest of World criteria

Journal of Ophthalmic Inflammation and Infection

Table 1 Recurrence related outcomes over 36 months based on USA and the Rest of World measurements of recurrence

	Rest of World^a		USA^b
	FAi (N = 87)	Sham treated (N = 42)	FAi (N = 87)	Sham treated (N = 42)
Recurrence
No recurrence, %	34.5	2.4	43.7	7.1
Recurrence rate, %	65.5	97.6	56.3	92.9
Observed, %	5.7	28.6	8.0	21.4
Imputed, %	59.8	69.0	48.3	71.4
Reason for imputation
Systemic treatments, %	28.7	11.9	31.0	21.4
Local injections, %	8.0	38.1	9.2	42.9
Topical medication, %	18.4	19.0	Not evaluated
Number of recurrences
Number of recurrences per eye, mean ± standard deviation	1.7 ± 2.4	5.3 ± 3.8	1.2 ± 2.0	4.0 ± 3.3
Eyes with ≤1 recurrence, %	67.8	14.3	78.2	26.1
Eyes with > 5 recurrences, %	8.0	40.5	2.3	26.2
Time to first recurrence
Time to, days, median	657	70.5	1051	95

^aRecurrence was defined as a ≥ 2 step increase in number of cells in the anterior chamber per high powered field or ≥ 2 step increase in vitreous haze or a loss in best-corrected visual acuity of ≥15 letters or the need for supplemental therapy (i.e., corticosteroids (systemic, injectable, or topical) or systemic immunosuppressants)
^bSame recurrence criteria with the exclusion of ≥2 step increase in number of cells in the anterior chamber per high powered field and the use of topical corticosteroids to define a recurrence